PE20220763A1 - Materiales y metodos para modular la inmunidad mediada por celulas t - Google Patents
Materiales y metodos para modular la inmunidad mediada por celulas tInfo
- Publication number
- PE20220763A1 PE20220763A1 PE2021001851A PE2021001851A PE20220763A1 PE 20220763 A1 PE20220763 A1 PE 20220763A1 PE 2021001851 A PE2021001851 A PE 2021001851A PE 2021001851 A PE2021001851 A PE 2021001851A PE 20220763 A1 PE20220763 A1 PE 20220763A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- cell
- Prior art date
Links
- 230000024932 T cell mediated immunity Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 102100022393 T cell receptor gamma variable 9 Human genes 0.000 abstract 2
- 101710151366 T cell receptor gamma variable 9 Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Referido a un anticuerpo que se une al receptor de celulas T gamma variable 9 (TRGV9), o fragmentos de union al antigeno de estos, caracterizado porque el anticuerpo comprende una region variable de cadena pesada (VH) y una region variable de cadena ligera (VL). En donde el anticuerpo comprende: (i) una VH que comprende una region determinante de complementariedad (CDR) 1 de VH que tiene una secuencia de aminoacidos de la sec. con num. de ident.:1, una CDR2 de VH que tiene una secuencia de aminoacidos de SEQ ID No:2, y una CDR3 de VH que tiene una secuencia de aminoacidos de la SEQ ID No:31; y (ii) una VL que comprende una CDR1 de VL que tiene una secuencia de aminoacidos de la SEQ ID No:4, una CDR2 de VL que tiene una secuencia de aminoacidos de la SEQ ID No:5, y una CDR3 de VL que tiene una secuencia de aminoacidos de la SEQ ID No:6. Tambien se refiere a acidos nucleicos que codifican los anticuerpos, un vector, una celula huesped que comprende el vector; un kit, una composicion farmaceutica que comprende dicho anticuerpo o fragmento de union al antigeno, un metodo para producir la composicion farmaceutica y su uso para tratar o prevenir enfermedades, tales como el cancer.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962844970P | 2019-05-08 | 2019-05-08 | |
| US201962844976P | 2019-05-08 | 2019-05-08 | |
| US201962844959P | 2019-05-08 | 2019-05-08 | |
| US201962844966P | 2019-05-08 | 2019-05-08 | |
| US201962844995P | 2019-05-08 | 2019-05-08 | |
| PCT/US2020/031749 WO2020227457A1 (en) | 2019-05-08 | 2020-05-07 | Materials and methods for modulating t cell mediated immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220763A1 true PE20220763A1 (es) | 2022-05-16 |
Family
ID=73051172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001851A PE20220763A1 (es) | 2019-05-08 | 2020-05-07 | Materiales y metodos para modular la inmunidad mediada por celulas t |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11667712B2 (es) |
| EP (1) | EP3965818A4 (es) |
| JP (2) | JP7686571B2 (es) |
| KR (1) | KR20220017892A (es) |
| CN (1) | CN113966231B (es) |
| AU (1) | AU2020267504A1 (es) |
| BR (1) | BR112021022089A2 (es) |
| CA (1) | CA3139508A1 (es) |
| CL (1) | CL2021002905A1 (es) |
| CO (1) | CO2021015998A2 (es) |
| CR (1) | CR20210548A (es) |
| DO (1) | DOP2021000229A (es) |
| EC (1) | ECSP21087921A (es) |
| IL (1) | IL287817A (es) |
| JO (1) | JOP20210297A1 (es) |
| MA (1) | MA55903A (es) |
| MX (1) | MX2021013532A (es) |
| PE (1) | PE20220763A1 (es) |
| PH (1) | PH12021552790A1 (es) |
| SG (1) | SG11202112021QA (es) |
| TW (1) | TW202108618A (es) |
| WO (1) | WO2020227457A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6743051B2 (ja) | 2015-01-27 | 2020-08-19 | ラヴァ・セラピューティクス・ベー・フェー | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
| WO2020060405A1 (en) | 2018-09-19 | 2020-03-26 | Lava Therapeutics B.V. | Dual acting cd1d immunoglobulin |
| IL295897A (en) * | 2020-02-27 | 2022-10-01 | Janssen Biotech Inc | Materials and methods for modulating an immune response |
| US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| IL299748A (en) | 2020-07-08 | 2023-03-01 | Lava Therapeutics N V | Antibodies that bind PSMA and T gamma delta receptors |
| EP4237003A4 (en) | 2020-10-28 | 2025-07-09 | Janssen Biotech Inc | COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY |
| EP4298125A1 (en) | 2021-02-26 | 2024-01-03 | LAVA Therapeutics N.V. | Antibodies that bind cd123 and gamma-delta t cell receptors |
| WO2025022361A1 (en) * | 2023-07-26 | 2025-01-30 | Janssen Biotech, Inc. | Materials and methods for cell growth |
| WO2025103451A1 (zh) * | 2023-11-15 | 2025-05-22 | 上海盛迪医药有限公司 | Trgv9结合蛋白及其医药用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2698880B1 (fr) * | 1992-11-25 | 1995-02-24 | Inst Nat Sante Rech Med | Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2003048328A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| WO2010045340A1 (en) | 2008-10-14 | 2010-04-22 | Centocor Ortho Biotech Inc. | Methods of humanizing and affinity-maturing antibodies |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| MX2012002766A (es) * | 2009-09-03 | 2012-04-02 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| CN103154026B (zh) | 2010-08-05 | 2016-07-06 | 安奈普泰斯生物有限公司 | 抗il-17的抗体 |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| NO2748201T3 (es) | 2011-08-23 | 2018-05-12 | ||
| WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| SI2794658T1 (sl) | 2011-12-19 | 2017-05-31 | Synimmune Gmbh | Bispecifična molekula protitelesa |
| WO2015061694A2 (en) * | 2013-10-25 | 2015-04-30 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta t cells for immunotherapy |
| KR102359264B1 (ko) | 2014-04-10 | 2022-02-04 | 라바 테라퓨틱스 비.브이. | 인간 Vγ9Vδ2 T 세포에 결합하는 면역글로불린 |
| SG11201701599UA (en) * | 2014-09-05 | 2017-03-30 | Janssen Pharmaceutica Nv | Cd123 binding agents and uses thereof |
| CN107249605A (zh) * | 2014-11-17 | 2017-10-13 | 阿迪塞特生物股份有限公司 | 工程化的γδT细胞 |
| US10144779B2 (en) | 2015-05-29 | 2018-12-04 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| US11117963B2 (en) | 2016-12-26 | 2021-09-14 | Kyowa Hakko Kirin Co., Ltd. | Antibody which binds to myelin oligodendrocyte glycoprotein |
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| US10519236B2 (en) * | 2018-01-23 | 2019-12-31 | New York University | Antibodies specific to delta 1 chain of T cell receptor |
| IL295897A (en) * | 2020-02-27 | 2022-10-01 | Janssen Biotech Inc | Materials and methods for modulating an immune response |
| US20210284731A1 (en) | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| EP4237003A4 (en) | 2020-10-28 | 2025-07-09 | Janssen Biotech Inc | COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY |
-
2020
- 2020-05-07 CA CA3139508A patent/CA3139508A1/en active Pending
- 2020-05-07 MX MX2021013532A patent/MX2021013532A/es unknown
- 2020-05-07 PH PH1/2021/552790A patent/PH12021552790A1/en unknown
- 2020-05-07 JO JOP/2021/0297A patent/JOP20210297A1/ar unknown
- 2020-05-07 TW TW109115171A patent/TW202108618A/zh unknown
- 2020-05-07 CR CR20210548A patent/CR20210548A/es unknown
- 2020-05-07 JP JP2021565723A patent/JP7686571B2/ja active Active
- 2020-05-07 BR BR112021022089A patent/BR112021022089A2/pt unknown
- 2020-05-07 SG SG11202112021QA patent/SG11202112021QA/en unknown
- 2020-05-07 KR KR1020217036132A patent/KR20220017892A/ko active Pending
- 2020-05-07 MA MA055903A patent/MA55903A/fr unknown
- 2020-05-07 WO PCT/US2020/031749 patent/WO2020227457A1/en not_active Ceased
- 2020-05-07 PE PE2021001851A patent/PE20220763A1/es unknown
- 2020-05-07 US US16/869,401 patent/US11667712B2/en active Active
- 2020-05-07 CN CN202080043002.2A patent/CN113966231B/zh active Active
- 2020-05-07 AU AU2020267504A patent/AU2020267504A1/en not_active Abandoned
- 2020-05-07 EP EP20801607.1A patent/EP3965818A4/en active Pending
-
2021
- 2021-11-03 IL IL287817A patent/IL287817A/en unknown
- 2021-11-04 DO DO2021000229A patent/DOP2021000229A/es unknown
- 2021-11-04 CL CL2021002905A patent/CL2021002905A1/es unknown
- 2021-11-26 CO CONC2021/0015998A patent/CO2021015998A2/es unknown
- 2021-12-03 EC ECSENADI202187921A patent/ECSP21087921A/es unknown
-
2023
- 2023-04-25 US US18/306,401 patent/US20240150464A1/en active Pending
-
2024
- 2024-08-07 JP JP2024131038A patent/JP2024170410A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP21087921A (es) | 2022-01-31 |
| AU2020267504A1 (en) | 2021-12-02 |
| US20240150464A1 (en) | 2024-05-09 |
| MA55903A (fr) | 2022-03-16 |
| EP3965818A1 (en) | 2022-03-16 |
| CA3139508A1 (en) | 2020-11-12 |
| TW202108618A (zh) | 2021-03-01 |
| DOP2021000229A (es) | 2022-07-31 |
| CO2021015998A2 (es) | 2021-12-10 |
| MX2021013532A (es) | 2022-02-11 |
| JP2024170410A (ja) | 2024-12-10 |
| IL287817A (en) | 2022-01-01 |
| BR112021022089A2 (pt) | 2022-02-08 |
| JOP20210297A1 (ar) | 2023-01-30 |
| CR20210548A (es) | 2022-02-11 |
| US11667712B2 (en) | 2023-06-06 |
| CN113966231A (zh) | 2022-01-21 |
| CN113966231B (zh) | 2025-04-01 |
| WO2020227457A1 (en) | 2020-11-12 |
| PH12021552790A1 (en) | 2022-09-05 |
| SG11202112021QA (en) | 2021-11-29 |
| EP3965818A4 (en) | 2023-05-31 |
| KR20220017892A (ko) | 2022-02-14 |
| CL2021002905A1 (es) | 2022-06-17 |
| JP2022533538A (ja) | 2022-07-25 |
| US20210032338A1 (en) | 2021-02-04 |
| JP7686571B2 (ja) | 2025-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20240096A1 (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| PE20251579A1 (es) | Anticuerpos especificos para cd70 y sus usos | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| AR123480A1 (es) | Moléculas de unión terapéuticas | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| RU2016141285A (ru) | Биспецифические антигенсвязывающие полипептиды | |
| JP2017511152A5 (es) | ||
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. |